Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class anti-CD39 antibody.
Location: United States, California, San Francisco
Investors 3
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| 22.09.2020 | Abingworth... | abingworth... |
| 23.01.2021 | Canaan Par... | canaan.com |